# Metric contract and acceptance checks

**Grain:** one named metric per fiscal year. **Unit:** USD millions. **Source:** selected values transcribed into `financial-metrics.csv` from the independent Pfizer portfolio analysis, with the basis recorded per row. This is a small illustrative extract; it is not an automated filing ingestion system.

| Field | Meaning | Control |
| --- | --- | --- |
| `metric` | Named financial measure | Exactly one record per metric and year |
| `fiscal_year` | 2024 or 2025 in this extract | No year is inferred |
| `amount_usd_millions` | Value in millions of US dollars | Blank remains NULL |
| `source_basis` | Filing or portfolio-calculation lineage | Required for each metric |

**Acceptance checks:** six expected metrics across two years; unique metric-year keys; a nonempty source basis; FY2024 missing CapEx remains NULL; FY2025 operating cash flow 11,704 less CapEx 2,629 matches both the calculated and supplied free cash flow of 9,075; operating cash flow divided by cash dividends paid rounds to 1.20; free cash flow minus dividends equals -696. The runner fails if those conditions are not met.

**Decision use:** the cash bridge and dividend measures can inform a question about headroom, with filing context and period definitions reviewed before use. This contract demonstrates analytics discipline with public data. It is not evidence of live deployment, client adoption, production service levels, or employer impact.